Asset Breakdown
22.9 M
Assets Non Current
22.6 M
Current Assets
| Total Assets | 49.22 Million | |
| Current Assets | 22.63 Million | |
| Assets Non Current | 22.88 Million |
Should I sell my Marker (NASDAQ:MRKR) holdings?
 | By Raphi Shpitalnik | Macroaxis Story |
The next fiscal quarter end is expected on the 31st of March 2021. The stock is currently experiencing an active upward rally. Marker Therapeutics Book Value per Share is relatively stable at the moment as compared to the past year. Marker Therapeutics reported last year Book Value per Share of 0.58. As of 03/19/2021, Current Ratio is likely to grow to 5.69, while Earnings before Tax are likely to drop (31 M). As many millenniums are trying to avoid healthcare space, it makes sense to sum up Marker Therapeutics a little further and try to understand its current market patterns. I will address a few possible reasons retail investors do not currently respect this stock.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
This firm currently holds 12.26 M in liabilities with Debt to Equity (D/E) ratio of 0.45, which is about average as compared to similar companies.
Marker Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.6253, which conveys a somewhat significant risk relative to the market. Let's try to break down what Marker's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Marker Therapeutics will likely underperform. Although it is vital to follow Marker Therapeutics price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. Our philosophy towards estimating future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Marker Therapeutics expected return of 1.08 will be sustainable into the future, we have found twenty-seven different technical indicators, which can help you to check if the expected returns are sustainable. Use Marker Therapeutics value at risk, as well as the relationship between the skewness and day median price to analyze future returns on Marker Therapeutics.
Marker Therapeutics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Marker Therapeutics, including all of Marker Therapeutics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Marker Therapeutics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Marker Therapeutics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page. Understanding Marker Total Liabilities
Marker Therapeutics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Marker Therapeutics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Marker Therapeutics balance sheet include debt obligations and money owed to different Marker Therapeutics vendors, workers, and loan providers. Below is the chart of Marker short long-term liabilities accounts currently reported on its balance sheet. You can use Marker Therapeutics financial leverage analysis tool to get a better grip on understanding its financial positionHow important is Marker Therapeutics's Liquidity
Marker Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Marker Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Marker Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Marker Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Marker Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Marker Therapeutics's total debt and its cash.
A Deeper Perspective On Marker Therapeutics
The company reported the previous year's revenue of 466.79 K. Net Loss for the year was (28.71 M) with loss before overhead, payroll, taxes, and interest of (18.41 M).
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Marker Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.